Projected cost-effectiveness of new vaccines for adolescents in the United States

Pediatrics

Volumn 121, Issue SUPPL. 1, 2008, Pages

  Ortega Sanchez, Ismael R ^a   Lee, Grace M ^b,c   Jacobs, R Jake ^d   Prosser, Lisa A ^b   Molinari, Noelle Angelique ^a   Zhang, Xinzhi ^e   Baine, William B ^f   McCauley, Mary M ^a   Miller, Ted ^g  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b HARVARD PILGRIM HEALTH CARE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d Capitol Outcomes Research Inc   (United States)

^e NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^f AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^g PACIFIC INSTITUTE FOR RESEARCH AND EVALUATION   (United States)

Author keywords

Adolescents; Cost effectiveness; Vaccines

Indexed keywords

HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; WART VIRUS VACCINE; HEPATITIS VACCINE; VACCINE;

ADOLESCENT; CONDYLOMA ACUMINATUM; COST CONTROL; COST EFFECTIVENESS ANALYSIS; ECONOMICS; EMBASE; HEALTH CARE; HEPATITIS A; HEPATITIS B; HERD IMMUNITY; HUMAN; IMMUNIZATION; INFLUENZA; MEDLINE; MENINGOCOCCOSIS; PERTUSSIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; UNITED STATES; COST BENEFIT ANALYSIS; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL;

ADOLESCENT; COST-BENEFIT ANALYSIS; HUMANS; INFLUENZA VACCINES; MODELS, ECONOMIC; PAPILLOMAVIRUS VACCINES; PERTUSSIS VACCINE; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES; VACCINES; VIRAL HEPATITIS VACCINES;

EID: 38449102883     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2007-1115H     Document Type: Review

References (68)

1. Centers for Disease Control and Prevention. Achievements in public health, 1900-1999 impact of vaccines universally recommended for children: United States, 1990-1998. MMWR Morb Mortal Wkly Rep. 1999;48:243-248
2. Zhou F, Santoli J, Messonnier ML, et al. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001. Arch Pediatr Adolesc Med. 2005;159: 1136-1144
3. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press;1996
4. Cohen R, Bloom B. Trends in health insurance and access to medical care for children under age 19 years: United States, 1998-2003. Adv Data. 2005;(355):1-12
5. Miller TR, Levy DT. Cost outcome analysis in injury prevention and control: a primer on methods. Inj Prev. 1997;3:288-293
6. Molla MT, Wagener DK, Madans JH. Summary measures of population health: methods for calculating healthy life expectancy. Healthy People 2010 Stat Notes. 2001;(21):1-11
7. Schwartz B, Ortega-Sanchez IR. Economic analyses of vaccines and vaccination programs. In: Levine MM, Woodrow GC, Kaper JB, Cobon GA, eds. New Generation Vaccines. New York, NY: Marcel Dekker, 2004:107-115
8. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. New York, NY: Oxford University Press; 1997
9. Meltzer MI. Introduction to health economics for physicians. Lancet. 2001;358:993-998
10. Centers for Disease Control and Prevention, Vaccine for Children Program. Pediatric/VFC vaccine price list. Available at:www.cdc.gov/vaccines/programs/ vfc/cdc-vac-price-list.htm# pediatric. Accessed July 7, 2007
11. Jacobs RJ, Margolis HS, Coleman PJ. The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates. Arch Pediatr Adolesc Med. 2000;154:763-770
12. Jacobs RJ, Saab S, Meyerhoff AS. The cost effectiveness of hepatitis immunization for US college students. J Am Coll Health. 2003;51:227-236
13. Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. A reappraisal of hepatitis B virus vaccination strategies using cost- effectiveness analysis. Ann Intern Med. 1993;118:298-306
14. Krahn M, Guasparini R, Sherman M, Detsky AS. Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program. Am J Public Health. 1998;88:1638-1644
15. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA. 1995;274:1201-1208
16. Zhou F, Euler GL, McPhee SJ, et al. Economic analysis of promotion of hepatitis B vaccinations among Vietnamese- American children and adolescents in Houston and Dallas. Pediatrics. 2003;111:1289-1296
17. Deuson RR, Brodovicz KG, Barker L, Zhou F, Euler GL. Economic analysis of a child vaccination project among Asian Americans in Philadelphia, Pa. Arch Pediatr Adolesc Med. 2001;155:909-914
18. Averhoff F, Shapiro CN, Bell BP, et al. Control of hepatitis A through routine vaccination of children. JAMA. 2001;286:2968-2973
19. Domínguez A, Salleras L, Carmona G, Batalla J. Effectiveness of a mass hepatitis A vaccination program in preadolescents. Vaccine. 2003;21:698-701
20. McIntosh ED. Pediatric infections: prevention of transmission and disease: implications for adults. Vaccine. 2005;23:2087-2089
21. Prosser LA, Bridges CB, Uyeki TM, et al. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis. 2006;12:1548-1558
22. Meltzer MI, Neuzil KM, Griffin MR, Fukuda K. An economic analysis of annual influenza vaccination of children. Vaccine. 2005;23:1004-1014
23. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis. 1999;5:659-671
24. US Congress, Office of Technology Assessment. Cost Effectiveness of Influenza Vaccination. Washington, DC: US Government Printing Office; 1981
25. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757-1765
26. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002; 347:1645-1651
27. Tomson TT, Roden RB, Wu TC. Human papillomavirus vaccines for the prevention and treatment of cervical cancer. Curr Opin Investig Drugs. 2004;5:1247-1261
28. Simon P. Progress towards a vaccine for cervical cancer. Curr Opin Obstet Gynecol. 2005;17:65-70
29. Stern PL. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J Clin Virol. 2005;32(suppl 1):72-81
30. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1-24
31. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003;290:781-789
32. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10: 1915-1923
33. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9:37-48
34. Hughes JP, Garnett GP, Koutsky L. The theoretical population- level impact of a prophylactic human papilloma virus vaccine. Epidemiology. 2002;13:631-639
35. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604-615
36. Institute of Medicine. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: National Academy of Sciences; 2000
37. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344:1378 -1388
38. Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR-7):1-21
39. Shepard CW, Ortega-Sanchez IR, Scott RD 2nd, Rosenstein NE; ABCs Team. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics. 2005;115:1220 -1232
40. Scott RD 2nd, Meltzer MI, Erickson LJ, De Wals P, Rosenstein NE. Vaccinating first-year college students living in dormitories for Meningococcal disease: an economic analysis. Am J Prev Med. 2002;23:98-105
41. Ortega-Sanchez IR, Meltzer MI, Shepard CW, et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the US. Clin Infect Dis. 2008; 46: In press
42. Raghunathan PL, Bernhardt SA, Rosenstein NE. Opportunities for control of meningococcal disease in the United States. Annu Rev Med. 2004;55:333-353
43. Imrey PB, Jackson LA, Ludwinski PH, et al. Outbreak of sero- group C meningococcal disease associated with campus bar patronage. Am J Epidemiol. 1996;143:624-630
44. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326:365-366
45. Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine-recommendations of the Advisory Committee on Immunization Practices, supported by the Healthcare Infection Control Practices Advisory Committee for use of Tdap among health-care personnel. MMWR Recomm Rep. 2006;55(RR-17):1-37
46. Iskedjian M, Walker JH, Hemels ME. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada. Vaccine. 2004;22:4215-4227
47. Purdy KW, Hay JW, Botteman MF, Ward JI. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis. 2004;39: 20-28
48. Lee GM, Lebaron C, Murphy TV, Lett S, Schauer S, Lieu TA. Pertussis in adolescents and adults: should we vaccinate? Pediatrics. 2005;115:1675-1684
49. Caro JJ, Getsios D, El Hadi W, Payne K, O'brien JA. Pertussis immunization of adolescents in the united states: an economic evaluation. Pediatr Infect Dis J. 2005;24:S75-S82
50. Lee GM, Lett S, Schauer S, et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis. 2004;39: 1572-1580
51. Van Rie A, Hethcote HW. Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine. 2004;22:3154-3165
52. Lieu TA, Ray G, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA. 2000;283:1460-1468
53. Strassels SA, Sullivan SD. Clinical and economic considerations of vaccination against varicella. Pharmacotherapy. 1997;17:133-139
54. Centers for Disease Control and Prevention. Vaccination coverage among children entering school: United States, 2003-04 School Year. MMWR Morb Mortal Wkly Rep. 2004;53:1041-1044
55. Grosse SD, Teutsch SM, Haddix AC. Lessons from cost- effectiveness research for United States public health policy. Annu Rev Public Health. 2007;28:365-391
56. Miller TR. Variations between countries in values of statistical life. J Trans Econ Policy. 2000;34:169-188
57. Viscusi WK, Aldy JE. The value of statistical life: a critical review of market estimates throughout the world. J Risk Uncertain. 2003;27:5-76
58. Gyrd-Hansen D. Willingness to pay for a QALY: theoretical and methodological issues. Pharmacoeconomics. 2005;23:423-432
59. Wang LY, Yang Q, Lowry R, Wechsler H. Economic analysis of a school-based obesity prevention program. Obes Res. 2003;11:1313-1324
60. Miller TR, Finkelstein EA, Zaloshnja E, Hendrie D. The cost of child and adolescent injuries and the savings from prevention, In: Liller K, ed. Injury Prevention for Children and Adolescents: Research, Practice, and Advocacy, Washington DC: American Public Health Association; 2005:15-64
61. Broder KR, Cohn AC, Schwartz B, et al. Adolescent immunizations and other clinical preventive services: a needle and a hook? Pediatrics. 2008;121:S25-S34
62. Szilagyi P, Rand CM, McLaurin J, et al. Delivering adolescent vaccinations in the medical home: a new era? Pediatrics. 2008;121:S15-S24
63. Lee GM, Salomon JA, LeBaron CW, Lieu TA. Health-state valuations for pertussis: methods for valuing short-term health states. Health Qual Life Outcomes. 2005;3:17
64. Griebsch I, Coast J, Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost- utility studies in child health. Pediatrics. 2005;115(5). Available at:www.pediatrics.org/cgi/ content/full/115/5/e600
65. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russel L. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1253-1258
66. Blumstein JF. The Oregon experiment: the role of cost-benefit analysis in the allocation of Medicaid funds. Soc Sci Med. 1997;45:545-554
67. Edgar A, Salek S, Shickle D, Cohen D. The Ethical QALY: Ethical Issues in Healthcare Resource Allocations. Haslemere, England: Euromed Communications; 1998
68. Centers for Disease Control and Prevention. Immunization of adolescents: recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association. MMWR Recomm Rep. 1996;45(RR-13):1-16